Lundbeck’s Williamson joins Avadel as CMO
Plus new CFO at Cellectis, and updates from 2seventy bio, City of Hope, Stablix and more
Douglas Williamson became CMO at Avadel Pharmaceuticals plc (NASDAQ:AVDL), which is developing therapies for narcolepsy. Williamson was most recently SVP, head of U.S. R&D and deputy global CMO at H. Lundbeck A/S (CSE:LUN). He also held several senior roles at Eli Lilly and Co. (NYSE:LLY) for 17 years, including as senior medical director of early phase neuroscience. Avadel’s FT218, a sodium oxybate formulation, is under review at FDA.
Gene editing platform company Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) hired Bing Wang as CFO. Wang was co-founder, CEO and director of Refuge Biotechnologies Inc. a cell therapy company which is using synthetic biology and gene engineering. Before Refuge, he was in healthcare investment banking for nearly a decade at Citigroup and Barclays Capital...